Nicholas M. Valiante

12.1k total citations · 7 hit papers
50 papers, 9.3k citations indexed

About

Nicholas M. Valiante is a scholar working on Immunology, Molecular Biology and Epidemiology. According to data from OpenAlex, Nicholas M. Valiante has authored 50 papers receiving a total of 9.3k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Immunology, 8 papers in Molecular Biology and 8 papers in Epidemiology. Recurrent topics in Nicholas M. Valiante's work include Immune Cell Function and Interaction (33 papers), T-cell and B-cell Immunology (25 papers) and Immunotherapy and Immune Responses (16 papers). Nicholas M. Valiante is often cited by papers focused on Immune Cell Function and Interaction (33 papers), T-cell and B-cell Immunology (25 papers) and Immunotherapy and Immune Responses (16 papers). Nicholas M. Valiante collaborates with scholars based in United States, Italy and Switzerland. Nicholas M. Valiante's co-authors include Annalisa D’Andrea, Giorgio Trinchieri, Peter Parham, Marek Kubin, Lewis L. Lanier, Miguel Aste-Amézaga, Derek T. O’Hagan, Xiaojing Ma, Heather Shilling and Markus Uhrberg and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and The Journal of Experimental Medicine.

In The Last Decade

Nicholas M. Valiante

50 papers receiving 9.1k citations

Hit Papers

Interleukin 10 (IL-10) inhibits human lymphocyte interfer... 1992 2026 2003 2014 1993 1992 1997 1997 2014 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells.
    1993 1.2k citations Annalisa D’Andrea, Miguel Aste-Amézaga et al. The Journal of Experimental Medicine profile →
  2. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells.
    1992 1.0k citations Annalisa D’Andrea, Manthrasalam Rengaraju et al. The Journal of Experimental Medicine profile →
  3. Human Diversity in Killer Cell Inhibitory Receptor Genes
    1997 878 citations Markus Uhrberg, Nicholas M. Valiante et al. Immunity profile →
  4. Functionally and Structurally Distinct NK Cell Receptor Repertoires in the Peripheral Blood of Two Human Donors
    1997 609 citations Nicholas M. Valiante, Markus Uhrberg et al. Immunity profile →
  5. mTOR inhibition improves immune function in the elderly
    2014 563 citations Nicholas M. Valiante et al. profile →
  6. Contact-dependent Stimulation and Inhibition of Dendritic Cells by Natural Killer Cells
    2002 554 citations Diego Piccioli, Nicholas M. Valiante et al. The Journal of Experimental Medicine profile →
  7. Nonviral delivery of self-amplifying RNA vaccines
    2012 525 citations Derek T. O’Hagan, Nicholas M. Valiante et al. profile →

Peers

Nicholas M. Valiante
Annalisa D’Andrea United States
Alana Althage United States
Andrea Cerutti United States
Carol Clayberger United States
Raymond P. Donnelly United States
Kasper Hoebe United States
David F. Tough United Kingdom
Hervé Groux France
Thomas J. Waldschmidt United States
Virginia Pascual United States
Annalisa D’Andrea United States
Nicholas M. Valiante
Citations per year, relative to Nicholas M. Valiante Nicholas M. Valiante (= 1×) peers Annalisa D’Andrea

Countries citing papers authored by Nicholas M. Valiante

Since Specialization
Citations

This map shows the geographic impact of Nicholas M. Valiante's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicholas M. Valiante with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicholas M. Valiante more than expected).

Fields of papers citing papers by Nicholas M. Valiante

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicholas M. Valiante. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicholas M. Valiante. The network helps show where Nicholas M. Valiante may publish in the future.

Co-authorship network of co-authors of Nicholas M. Valiante

This figure shows the co-authorship network connecting the top 25 collaborators of Nicholas M. Valiante. A scholar is included among the top collaborators of Nicholas M. Valiante based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicholas M. Valiante. Nicholas M. Valiante is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bertin, Paul A., Deepak Sharma, Andrew Anighoro, et al.. (2023). RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. Cell Reports Methods. 3(10). 100599–100599. 9 indexed citations
2.
Chiang, Chih-Yuan, Douglas Lane, Tim Hoffman, et al.. (2022). A Novel Toll-Like Receptor 2 Agonist Protects Mice in a Prophylactic Treatment Model Against Challenge With Bacillus anthracis. Frontiers in Microbiology. 13. 803041–803041. 2 indexed citations
3.
Buonsanti, Cecilia, Francesca Mancini, Marta Tontini, et al.. (2016). Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines. Scientific Reports. 6(1). 29063–29063. 35 indexed citations
4.
Aprea, Susanna, Tom Wu, M. Cooke, et al.. (2015). A new TLR2 agonist promotes cross-presentation by mouse and human antigen presenting cells. Human Vaccines & Immunotherapeutics. 11(8). 2038–2050. 23 indexed citations
5.
Crotta, Stefania, Michela Brazzoli, Diego Piccioli, Nicholas M. Valiante, & Andreas Wack. (2009). Hepatitis C virions subvert natural killer cell activation to generate a cytokine environment permissive for infection. Journal of Hepatology. 52(2). 183–190. 64 indexed citations
6.
Draghi, Monia, Achal Pashine, Bharati M. Sanjanwala, et al.. (2007). NKp46 and NKG2D Recognition of Infected Dendritic Cells Is Necessary for NK Cell Activation in the Human Response to Influenza Infection. The Journal of Immunology. 178(5). 2688–2698. 159 indexed citations
7.
Pashine, Achal, Nicholas M. Valiante, & Jeffrey B. Ulmer. (2005). Targeting the innate immune response with improved vaccine adjuvants. Nature Medicine. 11(S4). S63–S68. 435 indexed citations
8.
O’Hagan, Derek T. & Nicholas M. Valiante. (2003). Recent advances in the discovery and delivery of vaccine adjuvants. Nature Reviews Drug Discovery. 2(9). 727–735. 329 indexed citations
9.
Uhrberg, Markus, Nicholas M. Valiante, Neil T. Young, et al.. (2001). The Repertoire of Killer Cell Ig-Like Receptor and CD94:NKG2A Receptors in T Cells: Clones Sharing Identical αβ TCR Rearrangement Express Highly Diverse Killer Cell Ig-Like Receptor Patterns. The Journal of Immunology. 166(6). 3923–3932. 114 indexed citations
10.
Valiante, Nicholas M., Annalisa D’Andrea, Stefania Crotta, et al.. (2000). Life, activation and death of intrahepatic lymphocytes in chronic hepatitis C. Immunological Reviews. 174(1). 77–89. 82 indexed citations
11.
Shilling, Heather, et al.. (1998). Evidence for recombination as a mechanism for KIR diversification. Immunogenetics. 48(6). 413–416. 56 indexed citations
12.
Uhrberg, Markus, Nicholas M. Valiante, Benny P. Shum, et al.. (1997). Human Diversity in Killer Cell Inhibitory Receptor Genes. Immunity. 7(6). 753–763. 878 indexed citations breakdown →
13.
Valiante, Nicholas M., et al.. (1997). Killer cell receptors: keeping pace with MHC class I evolution. Immunological Reviews. 155(1). 155–164. 95 indexed citations
14.
Gumperz, Jenny E., Jacqueline C. M. Paterson, Virginia Litwin, et al.. (1996). Specificity of two anti‐class IHLA monoclonal antibodies that block class I recognition by the NKB1 killer cell inhibitory receptor. Tissue Antigens. 48(4). 278–284. 10 indexed citations
15.
Valiante, Nicholas M., Joseph H. Phillips, Lewis L. Lanier, & Peter Parham. (1996). Killer Cell Inhibitory Receptor Recognition of Human Leukocyte Antigen (HLA) Class I Blocks Formation of a pp36/PLC-γ Signaling Complex in Human Natural Killer (NK) Cells. The Journal of Experimental Medicine. 184(6). 2243–2250. 115 indexed citations
16.
Gumperz, Jenny E., Nicholas M. Valiante, Peter Parham, Lewis L. Lanier, & Dolly B. Tyan. (1996). Heterogeneous phenotypes of expression of the NKB1 natural killer cell class I receptor among individuals of different human histocompatibility leukocyte antigens types appear genetically regulated, but not linked to major histocompatibililty complex haplotype.. The Journal of Experimental Medicine. 183(4). 1817–1827. 132 indexed citations
17.
Valiante, Nicholas M. & Giorgio Trinchieri. (1993). Identification of a novel signal transduction surface molecule on human cytotoxic lymphocytes.. The Journal of Experimental Medicine. 178(4). 1397–1406. 192 indexed citations
18.
Bellone, Graziella, et al.. (1993). Regulation of hematopoiesis in vitro by alloreactive natural killer cell clones.. The Journal of Experimental Medicine. 177(4). 1117–1125. 44 indexed citations
19.
D’Andrea, Annalisa, Manthrasalam Rengaraju, Nicholas M. Valiante, et al.. (1992). Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells.. The Journal of Experimental Medicine. 176(5). 1387–1398. 1025 indexed citations breakdown →
20.
Trinchieri, Giorgio, Maria Wysocka, Annalisa D’Andrea, et al.. (1992). Natural killer cell stimulatory factor (NKSF) or interleukin-12 is a key regulator of immune response and inflammation. PubMed. 4(4). 355–368. 142 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Annalisa D’Andrea Breakdown of academic impact, for papers by Alana Althage Breakdown of academic impact, for papers by Andrea Cerutti Breakdown of academic impact, for papers by Carol Clayberger Breakdown of academic impact, for papers by Raymond P. Donnelly Breakdown of academic impact, for papers by Kasper Hoebe Breakdown of academic impact, for papers by David F. Tough Breakdown of academic impact, for papers by Hervé Groux Breakdown of academic impact, for papers by Thomas J. Waldschmidt Breakdown of academic impact, for papers by Virginia Pascual
Rankless by CCL
2026